1. Home
  2. SNDX
  3. SNDX News

Latest Syndax Pharmaceuticals Inc. (SNDX) News on March 29, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

GlobeNewswire

24 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...
SNDX

GuruFocus.com

24 days ago

Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...

SNDX

MT Newswires

25 days ago

B. Riley Cuts Price Target on Syndax Pharmaceuticals to $29 From $36, Keeps Buy Rating

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
SNDX

Zacks

a month ago

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

SNDX

MT Newswires

a month ago

Syndax Pharmaceuticals Q4 Loss Widens

SNDX

Associated Press Finance

a month ago

Syndax: Q4 Earnings Snapshot

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
SNDX

GlobeNewswire

a month ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result
SNDX

GuruFocus.com

a month ago

Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result

Syndax Announces Participation in March Investor Conferences
SNDX

GlobeNewswire

a month ago

Syndax Announces Participation in March Investor Conferences

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
SNDX

GlobeNewswire

a month ago

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
SNDX

Simply Wall St.

a month ago

Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

2 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in February Investor Conferences
SNDX

PR Newswire

2 months ago

Syndax Announces Participation in February Investor Conferences

SNDX

MT Newswires

2 months ago

Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
SNDX

PR Newswire

2 months ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
SNDX

PR Newswire

3 months ago

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain
SNDX

Simply Wall St.

3 months ago

Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
SNDX

PR Newswire

3 months ago

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

3 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
SNDX

PR Newswire

4 months ago

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
SNDX

PR Newswire

4 months ago

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
SNDX

Insider Monkey

4 months ago

Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

4 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
SNDX

PR Newswire

4 months ago

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Syndax secures FDA OK for new kind of leukemia drug
SNDX

BioPharma Dive

4 months ago

Syndax secures FDA OK for new kind of leukemia drug

FDA approves Syndax’s Revuforj to treat leukaemia
SNDX

Pharmaceutical Technology

4 months ago

FDA approves Syndax’s Revuforj to treat leukaemia

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
SNDX

PR Newswire

4 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
SNDX

Zacks

4 months ago

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
SNDX

Pharmaceutical Technology

5 months ago

Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint

Syndax’s revumenib meets primary results in AML trial
SNDX

TipRanks

5 months ago

Syndax’s revumenib meets primary results in AML trial

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
SNDX

Benzinga

5 months ago

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
SNDX

PR Newswire

5 months ago

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
SNDX

Simply Wall St.

5 months ago

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

SNDX

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Royalty Pharma PLC Earnings Call

SNDX

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Syndax Pharmaceuticals Inc Earnings Call

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
SNDX

BioPharma Dive

5 months ago

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale

Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
SNDX

GuruFocus.com

5 months ago

Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
SNDX

Zacks

5 months ago

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates

SNDX

Associated Press Finance

5 months ago

Syndax: Q3 Earnings Snapshot

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
SNDX

PR Newswire

5 months ago

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
SNDX

PR Newswire

5 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
SNDX

PR Newswire

5 months ago

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
SNDX

PR Newswire

5 months ago

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax agrees funding with Royalty Pharma for Niktimvo US sales
SNDX

Pharmaceutical Technology

5 months ago

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
SNDX

PR Newswire

5 months ago

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

5 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in November Investor Conferences
SNDX

PR Newswire

5 months ago

Syndax Announces Participation in November Investor Conferences

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
SNDX

PR Newswire

5 months ago

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

SNDX

MT Newswires

5 months ago

UBS Initiates Syndax Pharmaceuticals With Buy Rating, $37 Price Target

State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals
SNDX

GuruFocus.com

5 months ago

State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
SNDX

GuruFocus.com

6 months ago

Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

6 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
SNDX

PR Newswire

6 months ago

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
SNDX

Simply Wall St.

7 months ago

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

7 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
SNDX

Insider Monkey

7 months ago

Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
SNDX

Zacks

7 months ago

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
SNDX

Pharmaceutical Technology

7 months ago

FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
SNDX

Benzinga

7 months ago

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

SNDX

MT Newswires

7 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

SNDX

MT Newswires

7 months ago

Sector Update: Health Care

SNDX

MT Newswires

7 months ago

Incyte, Syndax Pharmaceuticals Get FDA Approval for Graft-Versus-Host Treatment

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
SNDX

Business Wire

7 months ago

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
SNDX

PR Newswire

8 months ago

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

8 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Despite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 years
SNDX

Simply Wall St.

8 months ago

Despite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 years

SNDX

Associated Press Finance

8 months ago

Syndax: Q2 Earnings Snapshot

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
SNDX

PR Newswire

8 months ago

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
SNDX

GlobeNewswire

8 months ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
SNDX

Investopedia

8 months ago

FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks

SNDX

MT Newswires

8 months ago

Syndax Pharmaceuticals Says US FDA Extends Revumenib Review; Shares Fall

Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
SNDX

PR Newswire

8 months ago

Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia

Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
SNDX

Zacks

8 months ago

Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet

Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
SNDX

PR Newswire

8 months ago

Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024

Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
SNDX

Zacks

9 months ago

Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

9 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

MT Newswires

9 months ago

Jefferies Initiates Syndax Pharmaceuticals at Buy With $37 Price Target

SNDX

MT Newswires

9 months ago

Stifel Raises Price Target on Syndax Pharmaceuticals to $42 From $40, Maintains Buy Rating

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
SNDX

PR Newswire

9 months ago

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
SNDX

GlobeNewswire

10 months ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

SNDX

MT Newswires

10 months ago

Syndax Pharmaceuticals to Progress into Phase 1b Segment of Revumenib Trial

Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
SNDX

PR Newswire

10 months ago

Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
SNDX

PR Newswire

10 months ago

Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

10 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
SNDX

PR Newswire

10 months ago

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
SNDX

Insider Monkey

a year ago

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
SNDX

PR Newswire

a year ago

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

SNDX

GuruFocus.com

a year ago

Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

SNDX

MT Newswires

a year ago

Syndax Pharmaceuticals Q1 Net Loss Widens

SNDX

Associated Press Finance

a year ago

Syndax: Q1 Earnings Snapshot

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
SNDX

PR Newswire

a year ago

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
SNDX

PR Newswire

a year ago

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
SNDX

PR Newswire

a year ago

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
SNDX

Zacks

a year ago

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
SNDX

PR Newswire

a year ago

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
SNDX

PR Newswire

a year ago

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
SNDX

PR Newswire

a year ago

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

Share on Social Networks: